Michael J. de la Merced / New York Times:
Isomorphic Labs, a DeepMind spinoff focusing on drug discovery, raised $600M led by Thrive to research treatments, including for cancer and immune disorders — The company, which uses artificial intelligence to develop new treatments, now counts the venture capital firm Thrive Capital as a backer.